ReviewMolecular oncology2016
Challenges in circulating tumor cell detection by the CellSearch system.
Review in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
191 citing papers in PubMed, 1 synthesis or guideline pooled it, 343 citations in OpenAlex.
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.Journal for immunotherapy of cancer · 2019Trial
- CellSearch-based isolation of circulating tumor cells from ascitic fluid enables molecular characterization of ovarian cancer.The journal of liquid biopsy · 2026Article
- Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.Exploration (Beijing, China) · 2026Review
- Liquid biopsy in bladder cancer: towards precision oncology.Journal of translational medicine · 2026Review
- Super homotypic targeting by surface engineering of extracellular vesicles.Nature biomedical engineering · 2026Article
- Article
- Band-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood.Lab on a chip · 2026Article
- Decoding CTCs in osteosarcoma: the molecular journey from initial tumor to metastasis.Scientific reports · 2026Article
- Liquid Biopsies in HNSCC: Current Landscape and Emerging Opportunities in the Era of HPV Stratification.International journal of molecular sciences · 2026Review
- PalmaClust: A graph-fusion framework leveraging the Palma ratio for robust ultra-rare cell type detection in scRNA-seq data.bioRxiv : the preprint server for biology · 2026Article
- Circulating Tumor Cells: Emerging Frontiers in Cancer Technology.Expert reviews in molecular medicine · 2026Review
- Genetic Alterations Involved in Immune Escape Mechanisms of Circulating Tumour Cells in Colorectal Carcinogenesis.Cancer medicine · 2026Review
- Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions.Cancers · 2026Review
- Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects.Biomedicines · 2026Review
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Frontiers in oncology · 2026Review
- Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective.Frontiers in immunology · 2026Review
- Circulating Tumor Cells for the Monitoring of Lung Cancer Therapies.International journal of molecular sciences · 2025Review
- Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer.Cancer cell international · 2025Article
131 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method designed for the enumeration of circulating tumor cells in 7.5 mL of blood. Presence of CTC detected by CellSearch is associated with poor prognosis in metastatic carcinomas. CTC remaining in patients after the first cycles of therapy indicates a futile therapy. Here we review challenges faced during the development of the CellSearch system and the difficulties in assigning objects as CTC. The large heterogeneity of CTC and the different approaches introduced in recent years to isolate, enumerate and characterize CTC results in a large variation of the number of CTC reported urging the need for uniform definitions and at least a clear definition of what the criteria are for assigning an object as a CTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.